Fernanda Palhano-Fontes

Research Engineer at the Brain Institute, UFRN

Data updated

Papers

24 publications

Trials

0 clinical trials

Research Footprint

Fernanda Palhano-Fontes appears in 24 tracked papers (2015–2026), most studied alongside Ayahuasca, DMT and LSD, across Healthy Volunteers, Depressive Disorders and Treatment-Resistant Depression (TRD).

Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).

Frequent co-authors: Draulio Araújo, Isabel Wießner and Lukas Wießner.

Publication Landscape

How the 24 papers Blossom tracks for Fernanda Palhano-Fontes line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Fernanda Palhano-Fontes's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

4papers published in 2022

+100% vs 2021

13 published by 2022

Browse papers

Don't read as total output: only the 24 of 24 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Fernanda Palhano-Fontes publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Fernanda Palhano-Fontes publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Fernanda Palhano-Fontes is a Brazilian neuroscientist and engineer whose pioneering research has validated the therapeutic potential of ayahuasca. Using fMRI and EEG, her work at the Federal University of Rio Grande do Norte (UFRN) has demonstrated the rapid antidepressant effects of the brew in controlled clinical settings, establishing her as a leading figure in South American psychedelic science.

Key Impact

Led the world's first double-blind, placebo-controlled trial of ayahuasca for treatment-resistant depression.

24

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

45 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Fernanda Palhano-Fontes's full collaboration network, shared papers, and research connections.

Affiliations

Institutions, companies, and organisations Fernanda Palhano-Fontes is associated with.